RA Capital Management Portfolio Companies

Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.

Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.

Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.

CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.

AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.

OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.

Palisade Bio is a clinical-stage biopharmaceutical company that develops therapies for acute and chronic gastrointestinal complications.

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Terrestrial Bio engages in developing biomedical innovations with a focus on improving access to vaccines.

Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs.

Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.

Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.